Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia

Zanubrutinib: First Approval

(2020) Yahiya Y. Syed   DRUGS

Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status

(2020) Kelly M. Kenzik et al.   JAMA Oncology

Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies

(2020) Julio Delgado et al.   HAEMATOLOGICA

Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro

(2020) Jan Habbel et al.   Blood Advances

Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation

(2020) Juan Liu et al.   Chemical Biology & Drug Design

Gilteritinib: First Global Approval

(2019) Sohita Dhillon   DRUGS

Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma

(2019) C. Owen et al.   Current Oncology

The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia

(2019) Yu Zhang et al.   CANCER GENE THERAPY

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?

(2019) Solène Fernandez et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Comparison of the Efficacy of Nilotinib and Imatinib in the Treatment of Chronic Myeloid Leukemia

(2019) Bang-Shuo Zhang et al.   JCPSP-Journal of the College of Physicians and Surgeons Pakistan

Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors

(2019) Marjan Yaghmaie et al.   Current Hematologic Malignancy Reports

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

(2019) Jan A. Burger et al.   LEUKEMIA

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

(2019) Linus Wahnschaffe et al.   Cancers

Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance

(2019) Ravi K. Patel et al.   PLoS One

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia

(2019) María Luz Morales et al.   Scientific Reports

Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo

(2018) Mark C. Weir et al.   ACS Chemical Biology

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

(2018) Elias Jabbour et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma

(2018) Enrico Tiacci et al.   BLOOD

Driver mutations in the mitogen-activated protein kinase pathway: the seeds of good and evil

(2018) H. Kittler et al.   BRITISH JOURNAL OF DERMATOLOGY

Precision therapy for acute myeloid leukemia

(2018) Xue Yang et al.   Journal of Hematology & Oncology

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy

(2018) Federico Rossari et al.   Journal of Hematology & Oncology

Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products

(2018) Kodappully S. Siveen et al.   Molecular Cancer

Mechanisms of receptor tyrosine kinase activation in cancer

(2018) Zhenfang Du et al.   Molecular Cancer

Kinase-targeted cancer therapies: progress, challenges and future directions

(2018) Khushwant S. Bhullar et al.   Molecular Cancer

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

(2018) Simona Soverini et al.   Molecular Cancer

Kinases and Cancer

(2018) Jonas Cicenas et al.   Cancers

A comprehensive review of protein kinase inhibitors for cancer therapy

(2018) Radhamani Kannaiyan et al.   Expert Review of Anticancer Therapy

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors

(2017) Sara Charmsaz et al.   EXPERIMENTAL HEMATOLOGY

Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression

(2017) G Barisione et al.   Blood Cancer Journal

Acute lymphoblastic leukemia: a comprehensive review and 2017 update

(2017) T Terwilliger et al.   Blood Cancer Journal

Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia

(2017) Amy N. Sexauer et al.   Frontiers in Pediatrics

The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment

(2017) Amr El Zawily et al.   Scientific Reports

Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas

(2016) A Nicolae et al.   LEUKEMIA

Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes

(2016) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment

(2016) James M. Paul et al.   Oncotarget

Idelalisib

(2015) Arpita Shah et al.   ANNALS OF PHARMACOTHERAPY

Eph Receptors and Ephrins: Therapeutic Opportunities

(2015) Antonio Barquilla et al.   Annual Review of Pharmacology and Toxicology

Ten things you should know about protein kinases: IUPHAR Review 14

(2015) Doriano Fabbro et al.   BRITISH JOURNAL OF PHARMACOLOGY

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications

(2015) L. Springuel et al.   HAEMATOLOGICA

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia

(2015) C. Vicente et al.   HAEMATOLOGICA

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia

(2015) Sandrine Degryse et al.   Journal of Hematology & Oncology

Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1

(2015) M S Zabriskie et al.   LEUKEMIA

Src family kinases and their role in hematological malignancies

(2015) Matthew Ku et al.   LEUKEMIA & LYMPHOMA

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System

(2015) K. R. Kampen et al.   MOLECULAR CANCER RESEARCH

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder

(2015) Anindya Chatterjee et al.   Oncotarget

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications

(2015) L. Springuel et al.   HAEMATOLOGICA

Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia

(2015) C. Vicente et al.   HAEMATOLOGICA

Ponatinib

(2014) Caitlin L. Shamroe et al.   ANNALS OF PHARMACOTHERAPY

SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia

(2014) Alexandre Puissant et al.   CANCER CELL

Ibrutinib: First Global Approval

(2014) Fiona Cameron et al.   DRUGS

Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center

(2014) Ya-Zhen Qin et al.   LEUKEMIA RESEARCH

Expression of Eph A4, Eph B2 and Eph B4 Receptors in AML

(2014) Tomasz Wrobel et al.   PATHOLOGY & ONCOLOGY RESEARCH

Getting Syk: spleen tyrosine kinase as a therapeutic target

(2014) Robert L. Geahlen   TRENDS IN PHARMACOLOGICAL SCIENCES

Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic

(2014) Muneera Al-Hussaini et al.   Expert Review of Hematology

The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents

(2013) C. Dos Santos et al.   BLOOD

Discoidin domain receptors in disease

(2013) Corina M. Borza et al.   MATRIX BIOLOGY

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia

(2013) Steffen Koschmieder et al.   OncoTargets and Therapy

Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model

(2012) S. Greenblatt et al.   BLOOD

Discoidin domain receptor tyrosine kinases: new players in cancer progression

(2012) Rajeshwari R. Valiathan et al.   CANCER AND METASTASIS REVIEWS

Functions of the Lyn tyrosine kinase in health and disease

(2012) Evan Ingley   Cell Communication and Signaling

Copy Number Variations of EphA3 Are Associated With Multiple Types of Hematologic Malignancies

(2012) Ming Guan et al.   Clinical Lymphoma Myeloma & Leukemia

Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia

(2012) Kumudha Balakrishnan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia

(2012) M C Chillón et al.   LEUKEMIA

JAK/STAT signaling in hematological malignancies

(2012) W Vainchenker et al.   ONCOGENE

Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma

(2012) Ghee Chong Koo et al.   Cancer Discovery

B-cell receptor signaling in chronic lymphocytic leukemia

(2011) F. K. Stevenson et al.   BLOOD

The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma

(2011) Elisa Oricchio et al.   CELL

Raf kinases in cancer–roles and therapeutic opportunities

(2011) G Maurer et al.   ONCOGENE

The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy

(2010) A. K. Ghosh et al.   BLOOD

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

(2010) J. A. Pollard et al.   BLOOD

Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia

(2010) S.-Q. Kuang et al.   BLOOD

The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy

(2010) Christopher Lieu et al.   Clinical Colorectal Cancer

Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies

(2009) Kais Hussein et al.   ANNALS OF HEMATOLOGY

Characterization of the CHK1 Allosteric Inhibitor Binding Site

(2009) Darin Vanderpool et al.   BIOCHEMISTRY

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Proteomic and Genetic Approaches Identify Syk as an AML Target

(2009) Cynthia K. Hahn et al.   CANCER CELL

Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia

(2009) Maike Buchner et al.   CANCER RESEARCH

Mechanisms of resistance to FLT3 inhibitors

(2009) S. Haihua Chu et al.   DRUG RESISTANCE UPDATES

STAT5 Activation Is Critical for the Transformation Mediated by Myeloproliferative Disorder-associated JAK2 V617F Mutant

(2009) Megumi Funakoshi-Tago et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia

(2009) Lauren Véronèse et al.   LEUKEMIA RESEARCH

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression

(2009) A D Baudot et al.   ONCOGENE

RNAi screen for rapid therapeutic target identification in leukemia patients

(2009) J. W. Tyner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acquired copy number alterations in adult acute myeloid leukemia genomes

(2009) M. J. Walter et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical implications of c-Kit mutations in acute myelogenous leukemia

(2009) Muriel Malaise et al.   Current Hematologic Malignancy Reports

Development of thioquinazolinones, allosteric Chk1 kinase inhibitors

(2008) Antonella Converso et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells

(2008) S. H. Wimmer-Kleikamp et al.   BLOOD

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia

(2008) M. M. Loriaux et al.   BLOOD

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

(2008) R. M. Young et al.   BLOOD

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia

(2008) M. H. Tomasson et al.   BLOOD

Therapeutic Protein Kinase Inhibitors

(2008) S. K. Grant   CELLULAR AND MOLECULAR LIFE SCIENCES

Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

(2008) S. Baskar et al.   CLINICAL CANCER RESEARCH

Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia

(2008) Elisabetta Flex et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Systematic genomic screen for tyrosine kinase mutations in CLL

(2008) J R Brown et al.   LEUKEMIA

Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas

(2008) A L Feldman et al.   LEUKEMIA

Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells

(2008) Luis M. Alonso-C et al.   LEUKEMIA RESEARCH

Nilotinib for the treatment of chronic myeloid leukemia

(2008) Theo Daniel Kim et al.   Expert Review of Hematology

Identification of somatic JAK1 mutations in patients with acute myeloid leukemia

(2007) Z. Xiang et al.   BLOOD